From: An observational study of the discrediting of COX-2 NSAIDs in Australia: Vioxx or class effect?
 | Continuous Users | Non-Continuous Users | IRR (95% CI) | ||||
---|---|---|---|---|---|---|---|
Medicine | Na | Cases | Incidence rate (per 100,000 person days) | Na | Cases | Incidence rate (per 100,000 person days) | Â |
COX-2s Overall | 163 | 130 | 272.2 | 320 | 146 | 58.8 | 4.6 (3.6,5.9) |
Celecoxib | 163 | 59 | 44.9 | 320 | 54 | 16.7 | 2.7 (1.8,4) |
Lumiracoxib | 163 | 12 | 6.7 | 320 | 17 | 4.7 | 1.4 (0.6,3.2) |
Meloxicam | 163 | 98 | 111.3 | 320 | 100 | 34.8 | 3.2 (2.4,4.3) |
ns-NSAIDs Overall | 137 | 56 | 47.9 | 274 | 101 | 40.7 | 1.2 (0.8,1.6) |
Diclofenac | 137 | 14 | 9.6 | 274 | 24 | 8.0 | 1.2 (0.6,2.4) |
Ibuprofen | 137 | 10 | 6.6 | 274 | 15 | 4.9 | 1.4 (0.5,3.2) |
Naproxen | 137 | 10 | 6.6 | 274 | 8 | 2.6 | 2.6 (0.9,7.5) |
Piroxicam | 137 | 43 | 33.2 | 274 | 95 | 37.9 | 0.9 (0.6,1.3) |
Acetylsalicylic acid | 137 | 4 | 2.6 | 274 | 3 | 1.0 | 2.7 (0.5,18.4) |
Other ns-NSAIDs | 137 | 5 | 3.2 | 274 | 9 | 2.9 | 1.1 (0.3,3.7) |
Opioids Overall | 143 | 45 | 32.5 | 321 | 86 | 26.7 | 1.2 (0.8,1.8) |
Buprenorphine | 143 | 5 | 3.0 | 321 | 12 | 3.2 | 0.9 (0.3,2.9) |
Morphine | 143 | 5 | 3.0 | 321 | 19 | 5.1 | 0.6 (0.2,1.6) |
Oxycodone | 143 | 15 | 9.3 | 321 | 33 | 9.2 | 1 (0.5,1.9) |
Tramadol | 143 | 36 | 25.5 | 321 | 52 | 15.5 | 1.7 (1,2.6) |
Other Opioids | 143 | 2 | 1.2 | 321 | 4 | 1.1 | 1.1 (0.1,7.9) |
Paracetamol Overall | 71 | 56 | 138.0 | 171 | 96 | 76.6 | 1.8 (1.3,2.5) |
Paracetamol and combinations excl. psycholeptics | 71 | 56 | 138.0 | 171 | 96 | 76.4 | 1.8 (1.3,2.5) |
Codeine, combinations excl. psycholeptics | 71 | 3 | 3.7 | 171 | 6 | 3.1 | 1.2 (0.2,5.6) |